Evidence map›Paper›PMID 30504844›Full record

ArticleNature communications2018

ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling.

Andreia V Pinho, Mathias Van Bulck, Lorraine Chantrill, Mehreen Arshi, Tatyana Sklyarova, David Herrmann, Claire Vennin, David Gallego-Ortega, Amanda Mawson, Marc Giry-Laterriere and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 57 citations in OpenAlex.

  1. The CaThe Journal of biological chemistry · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 5 countries.

Andreia V PinhoCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia. andreia.pinho@mq.edu.au.ORCID http://orcid.org/0000-0003-0647-4015
Mathias Van BulckOncology Research Centre, Vrije Universiteit Brussel, Brussels, 1090, Belgium.
Lorraine ChantrillCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
Mehreen ArshiCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
Tatyana SklyarovaOncology Research Centre, Vrije Universiteit Brussel, Brussels, 1090, Belgium.ORCID http://orcid.org/0000-0002-7536-6977
David HerrmannCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.ORCID http://orcid.org/0000-0002-9514-7501
Claire VenninCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
David Gallego-OrtegaCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.ORCID http://orcid.org/0000-0002-2347-7835
Amanda MawsonCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.ORCID http://orcid.org/0000-0002-2534-6492
Marc Giry-LaterriereCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
Astrid MagenauCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
Gunther LeuckxBeta cell Neogenesis Lab, Vrije Universiteit Brussel, Brussels, 1090, Belgium.
Luc BaeyensBeta cell Neogenesis Lab, Vrije Universiteit Brussel, Brussels, 1090, Belgium.
Anthony J GillCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
Phoebe PhillipsLowy Cancer Research Centre, University of New South Wales, Sydney, Sydney 2052, NSW, Australia.
Paul TimpsonCancer Division, The Garvan Institute of Medical Research, Sydney, Darlinghurst 2010, NSW, Australia.
Andrew V BiankinAustralian Pancreatic Cancer Genome Initiative (APGI), Sydney, Darlinghurst 2010, NSW, Australia.ORCID http://orcid.org/0000-0002-0362-5597
Jianmin WuAustralian Pancreatic Cancer Genome Initiative (APGI), Sydney, Darlinghurst 2010, NSW, Australia.ORCID http://orcid.org/0000-0002-8876-128X
Ilse RoomanAustralian Pancreatic Cancer Genome Initiative (APGI), Sydney, Darlinghurst 2010, NSW, Australia. irooman@vub.be.
Garvan Institute of Medical Research · AUVrije Universiteit Brussel · BECancer Institute of New South Wales · AUGlasgow Royal Infirmary · GBPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whereas genomic aberrations in the SLIT-ROBO pathway are frequent in pancreatic ductal adenocarcinoma (PDAC), their function in the pancreas is unclear. Here we report that in pancreatitis and PDAC mouse models, epithelial Robo2 expression is lost while Robo1 expression becomes most prominent in the stroma. Cell cultures of mice with loss of epithelial Robo2 (Pdx1

Indexed as

AnimalsBlotting, WesternCarcinoma, Pancreatic DuctalCells, CulturedFemaleFlow CytometryHomeodomain ProteinsIn Situ HybridizationIn Vitro TechniquesMaleMiceNerve Tissue ProteinsPancreasPancreatitisReceptors, ImmunologicRoundabout ProteinsHomeodomain ProteinsNerve Tissue Proteinspancreatic and duodenal homeobox 1 proteinReceptors, ImmunologicRobo2 protein, mouseRoundabout ProteinsTrans-ActivatorsTransforming Growth Factor beta

Identifiers

PMID30504844
PMCPMC6269509
OpenAlexW2902532516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.